OverviewSuggest Edit

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutics to improve the lives of patients with serious diseases. The Company currently has three product candidates in clinical development covering multiple potential indications. Cabiralizumab (FPA008) is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis and in multiple cancers in combination with Bristol-Myers Squibb Company’s PD-1 immune checkpoint inhibitor, Opdivo (nivolumab). FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that we are initially developing to treat patients with gastric (stomach) cancer and is in a Phase 1 clinical trial. FP-1039 is a fusion protein that “traps” and neutralizes cancer-promoting fibroblast growth factors, or FGFs, involved in cancer cell proliferation and new blood vessel formation that is in Phase 1b clinical development to treat patients with malignant pleural mesothelioma.

TypePublic
Founded2001
HQSouth San Francisco, US
Websitefiveprime.com
Employee Ratings2.4

Latest Updates

Employees (est.) (Jan 2019)168(-19%)
Job Openings10
Share Price (Mar 2019)$13.1 (-3%)

Key People/Management at Five Prime Therapeutics

Aron Knickerbocker

Aron Knickerbocker

CEO
Francis Sarena

Francis Sarena

Chief Strategy Officer and Secretary
Jeff Coon

Jeff Coon

Senior Vice President, Human Resources
Helen Collins

Helen Collins

Senior Vice President and Chief Medical Officer
Bryan Irving

Bryan Irving

Executive Vice President and Chief Scientific Officer
Nallakkan S. Arvindan

Nallakkan S. Arvindan

Senior Vice President, Strategic Technology Operations
Show more

Five Prime Therapeutics Office Locations

Five Prime Therapeutics has an office in South San Francisco
South San Francisco, US (HQ)
2 Corporate Dr
Show all (1)
Report incorrect company information

Five Prime Therapeutics Financials and Metrics

Five Prime Therapeutics Revenue

USD

Net income (FY, 2018)

(140.4m)

EBIT (FY, 2018)

(146.2m)

Market capitalization (22-Mar-2019)

463.8m

Closing stock price (22-Mar-2019)

13.1

Cash (31-Dec-2018)

44.0m
Five Prime Therapeutics's current market capitalization is $463.8 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017FY, 2018

General and administrative expense

10.4m22.6m35.8m40.0m39.7m

R&D expense

32.8m70.2m94.1m150.9m156.4m

Operating expense total

43.2m92.8m129.9m190.9m196.0m

EBIT

(29.4m)287.0m(99.2m)(151.4m)(146.2m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

2.6m3.3m3.0m3.4m4.6m5.2m8.6b8.1b9.1m10.5m9.4m9.7m10.5m9.8m

R&D expense

8.2m8.9m11.9m9.8m13.3m24.7m18.3b22.2b23.9m33.8m41.7m42.7m43.6m33.4m

Operating expense total

10.8m12.2m14.9m13.2m17.9m29.9m26.9b30.3b33.0m44.2m51.1m52.4m54.0m43.2m

EBIT

(7.3m)(8.7m)(9.9m)(7.1m)(11.6m)(24.1m)(20.4b)(21.1b)(26.4m)(34.1m)(43.3m)(44.1m)(21.5m)(35.6m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

8.2m15.3m150.0m7.7m59.8m44.0m

Accounts Receivable

Inventories

Current Assets

77.7m151.3m528.3m440.1m311.2m288.6m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(28.9m)(37.4m)249.6m(65.7m)(150.2m)

Depreciation and Amortization

1.7m1.6m1.7m1.7m2.5m5.0m

Inventories

Accounts Payable

(209.0k)701.0k798.0k(1.6m)1.9m(265.0k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(11.5m)(24.0m)(13.0b)(13.1b)(19.4b)(33.4b)(43.3b)

Accounts Payable

3.8m347.0k767.0k672.0k904.0k1.4m1.6m1.0m654.0k528.0k807.0k1.3m2.9m
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Five Prime Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Five Prime Therapeutics News and Updates

Report incorrect company information

Five Prime Therapeutics Blogs

Five Prime Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

Significant Pipeline Expansion and Strong Clinical Execution in 2018 Phase 3 FIGHT Registrational Trial in Gastric and GEJ Cancer Enrolling Phase 2 Cabiralizumab/ Opdivo ® (nivolumab) Trial in Pancreatic Cancer Enrolling Phase 1 Starts for FPA150, FPT155 and BMS-986258 Multiple Data Readouts in

Five Prime Therapeutics Doses First Patient in Phase 1b Trial of FPA150

First-in-class antibody targeting B7-H4 Dual mechanism blocks a T cell checkpoint pathway and delivers potent antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells that express B7-H4 B7-H4 is over-expressed on hard-to-treat solid tumors with low response to checkpoint inhibition

Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26

Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on February 26 Content Import Thu, 02/07/2019 - 16:10 Five Prime Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Februar…

Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum

Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum Content Import Mon, 02/04/2019 - 17:07 Five Prime Therapeutics to Present at the Guggenheim Healthcare Talks Idea Forum February 4, 2019 at 5:05 PM EST This release is a backfill …

Jonathan Chang

Jonathan Chang ryan.manuel Wed, 01/23/2019 - 18:59 Jonathan Chang Leerink Partners jonathan.chang@leerink.com

Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium

Five Prime Therapeutics Presents Data from Safety Lead-in to Phase 3 FIGHT Trial of Bemarituzumab at 2019 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium Content Import Thu, 01/17/2019 - 14:08 Five Prime Therapeutics Presents Data from Safety Lead-in to…
Show more

Five Prime Therapeutics Frequently Asked Questions

  • When was Five Prime Therapeutics founded?

    Five Prime Therapeutics was founded in 2001.

  • Who are Five Prime Therapeutics key executives?

    Five Prime Therapeutics's key executives are Aron Knickerbocker, Francis Sarena and Jeff Coon.

  • How many employees does Five Prime Therapeutics have?

    Five Prime Therapeutics has 168 employees.

  • Who are Five Prime Therapeutics competitors?

    Competitors of Five Prime Therapeutics include Heat Biologics, Immune Design and Geron.

  • Where is Five Prime Therapeutics headquarters?

    Five Prime Therapeutics headquarters is located at 2 Corporate Dr, South San Francisco.

  • Where are Five Prime Therapeutics offices?

    Five Prime Therapeutics has an office in South San Francisco.

  • How many offices does Five Prime Therapeutics have?

    Five Prime Therapeutics has 1 office.